Exercise is the Other Half of the GLP-1 Equation — Here's Why
Millions of Americans are currently taking GLP-1 medications and new research is make the case that resistance training isn't just complementary to the medication. It's essential to it. In Episode 9 of The Research Debrief, hosts Rachel Chonko and Luke Carlson examine what the latest science says about muscle loss during GLP-1 treatment — and why health clubs are uniquely positioned to serve their members who use the medication. This Episode Covers: - How much muscle mass is lost during GLP-1 drug therapy and what clinical trial data reveals about the scope of that loss. - The two key factors critical to preserving lean muscle during weight reduction — and why one of them falls squarely within the scope of what health clubs provide. - What the science says about the long-term consequences of stopping GLP-1 therapy, including which outcomes exercise has been shown to mitigate. - How the profile of a GLP-1 drug user compares to the profile of a typical health club member — and what that overlap means for operators. - Why physicians prescribing GLP-1 medications are increasingly looking to fitness facilities as partners in patient care, and how clubs can position themselves to meet that demand GLP-1 drugs are reshaping the healthcare landscape at scale, and the fitness industry has a scientifically validated role to play. Clubs that build programming, messaging and referral relationships around this now will be best positioned to grow their member base and their influence within the healthcare continuum. 📚 Access the show notes page for links to the research papers discussed: 🎧 Listen on Apple Podcasts, Spotify or SoundCloud 📺 Watch right here on YouTube 👉 Stay ahead of fitness, leadership and research Subscribe to the Club Solutions newsletter to receive industry insights, trends and research-driven strategies delivered straight to your inbox: clubsolutionsmagazine.com/newsletter/